Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-17
2011-05-17
Goldberg, Jeanine A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07943317
ABSTRACT:
This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
REFERENCES:
patent: 7781168 (2010-08-01), Iakoubova et al.
patent: 2005/0272054 (2005-12-01), Cargill et al.
patent: 2005/0287558 (2005-12-01), Crooke et al.
patent: 2006/0199239 (2006-09-01), Gurbel
patent: 2007/0099242 (2007-05-01), Heinecke et al.
patent: WO 2004/058082 (2004-07-01), None
Cavallari et al. (Current Treatment options in cardiovascular medicine, vol. 11, pp. 191-200, 2009).
Shiffman et al. (Arterioscler Thromb Vasc Biol. vol. 29, No. 7, pp. e10, Jul. 2009).
Shiffman et al (Thromb Haemost, vol. 102, pp. 179-180, 2009).
Chasman et al. (Atherosclerosis, vol. 203, No. 2, pp. 371-376, Apr. 2009).
Akaike et al., Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. Sep. 2002;48(9):1454-9.
Chasman et al., Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. Apr. 2009;203(2):371-6. Epub ahead of print Jul. 26, 2008.
Eisenstein et al., Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. Jan. 10, 2007;297(2):159-68. Epub Dec. 5, 2006.
Kagawa et al., Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem. Nov. 1999 26;274(48):34111-5.
Luke et al., A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. Sep. 2007;27(9):2030-6. Epub Jun. 14, 2007.
Ridker et al., A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. Mar. 31, 2005;352(13):1293-304. Epub Mar. 7, 2005.
Shiffman et al., Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. Jul. 2009;102(1):179-80.
Suk Danik et al., Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. Sep. 20, 2006;296(11):1363-70.
Mar. 2006 assembly—NCBI build 36.1; rs3798220 dbSNP @ NCBI. Printed Aug. 26, 2008. Best available copy.
NCBI build 128; rs9457931 dbSNP @ NCBI (2006). Printed Aug. 26, 2008. Best available copy.
NCBI build 128; rs9457927 dbSNP @NCBI (2006). Printed Aug. 26, 2008. Best available copy.
NCBI SNP database. rs3798220. Printed Dec. 15, 2010.
NCBI SNP database. rs9457927. Printed Dec. 15, 2010.
NCBI SNP database. rs9457931. Printed Dec. 15, 2010.
Chasman Daniel
Ridker Paul
Shiffman Dov
Applera Corporation
Goldberg Jeanine A
The Brigham and Women's Hospital, Inc.
LandOfFree
Polymorphism in the Apo(a) gene predict responsiveness to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphism in the Apo(a) gene predict responsiveness to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphism in the Apo(a) gene predict responsiveness to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689961